Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Hepatitis and HIV news

Show

From To
AbbVie Announces New Phase 3b Results in Genotype 1b Chronic Hepatitis C Patients with Compensated Liver Cirrhosis

AbbVie, a global biopharmaceutical company, today announced TURQUOISE-III study results demonstrating 100 percent (n=60/60) sustained virologic response at 12 weeks post-treatment (SVR12) in genotype 1b (GT1b) chronic hepatitis C virus (HCV) infected adult patients with compensated liver cirrhosis. These new results from AbbVie's Phase 3b study will be presented at the 15th Annual International Symposium on Viral Hepatitis and Liver Diseases in Berlin, Germany.

Published
24 June 2015
From
AbbVie press release
Burman's Specialty Pharmacy study shows hepatitis C cure possible while cutting a third of the drug costs

Burman's Specialty Pharmacy, a Diplomat company, announced a study showing that more than a quarter of hepatitis C patients may be treated with an eight-week therapy, four weeks shorter than the drug manufacturers originally expected. This represents potential for a huge cost savings in a health care ecosystem where hepatitis C treatments have posed a looming problem for payor organizations.

Published
24 June 2015
From
Burman's Specialty Pharmacy press release
China rejects Gilead hepatitis C drug patent: advocacy group

China has rejected a Gilead Sciences Inc patent application related to its costly hepatitis C drug, a U.S. advocacy group said, adding the move may lead to other countries to consider rejecting patents for the controversial treatment.

Published
19 June 2015
From
Reuters
Liver function and survival improve after treatment with Viekirax + Exviera regimen

Hepatitis C patients treated with AbbVie's Viekirax plus Exviera or '3D' regimen saw improvements in liver function biomarkers, had better quality of life and had increased survival

Published
18 June 2015
By
Liz Highleyman
Hepatitis C: 25 Years Old, and Fading

At this year's Digestive Disease Week, investigators discussed issues related to screening efforts, the natural history of HCV infection, the safety and efficacy of the next wave of antiviral agents, access to care, and affordability of treatment.

Published
17 June 2015
From
Medscape
NHS accused of delaying access to 'highly tolerable' hepatitis C drugs over cost concerns

The NHS has been accused by leading health charities of attempting to “severely limit” the introduction of new drugs to treat hepatitis C because they are too expensive – despite the cost of them being cleared by officials.

Published
17 June 2015
From
The Independent
Hepatitis cases responsible for 93% of prison disease reports

The increase in reports reflects significant improvements in testing for hepatitis and other blood borne viruses (BBV) in prisons, which in a major change is moving from an ‘opt-in’ to an ‘opt-out’ policy to help reduce transmissions.

Published
16 June 2015
From
Public Health England press release
Prisoners Sue Massachusetts for Withholding Hepatitis C Drugs

In the latest example of how the high price tags for hepatitis C drugs are limiting use in some of the most infected populations, two inmates in Massachusetts state prisons have filed a lawsuit accusing the state prison system of failing to provide the drugs to most infected prisoners.

Published
16 June 2015
From
Wall Street Journal (blog)
NHS England announces 'huge investment' for new hepatitis C treatments

“This is a huge new investment,” says Richard Jeavons, NHS England’s director of specialised services. “That’s why we’re also running a competitive tendering process in parallel, to seek to bring down the price of these very expensive new drugs.”

Published
16 June 2015
From
The Pharmaceutical Journal
HCV at a Crossroads:The Pre- or Post-Transplant Treatment Debate

Hepatitis C virus infection is the leading indication for liver transplantation, with nearly half of registrants on the liver transplantation list infected with the virus. In today’s era, patients have the option to be treated for the infection before or after transplantation. HCV Next spoke to several experts on liver transplantation and discussed the best time they believe to treat HCV is — before or after undergoing a liver transplant — and what providers should keep in mind when beginning therapy.

Published
15 June 2015
From
Healio HCV Next

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.